NCT00756262终止1 期
Probiotic Lactobacillus GG to Eliminate VRE Colonization
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 11
- 试验地点
- 2
- 主要终点
- The primary endpoint will be the proportion of patients with VRE at one week after cessation of administration of study medication or placebo.
研究概览
简要总结
The use of LGG will be associated with elimination of VRE colonization.
The primary comparison will be VRE elimination rates among those patients that receive LGG compared to those that receive placebo. The primary endpoint will be the proportion of patients with VRE at one week after cessation of administration of study medication or placebo. The investigators assume that the placebo group will have very little spontaneous elimination of VRE and that the LGG group will be more likely to have eliminated VRE colonization at the end of one week.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age greater than or equal to 18 years
- •Identified as having had a clinical isolate or stool or rectal swab culture positive for VRE
- •Able to give informed consent and report on side effects
- •Tolerating an oral/enteral diet
- •Stable comorbid conditions
- •Willing and able to come to Tufts for weekly visits
排除标准
- •Active infection with VRE being treated
- •Known use of LGG or another probiotic (not including yogurt) within the previous 30 days
- •Presence of an active bowel leak, acute abdomen, active intestinal disease, or significant bowel dysfunction
- •Presence of an absolute neutrophil count less than 500 per cubic mm or anticipation post chemotherapy that the absolute neutrophil count will fall below 500 per cubic mm
- •History of adverse reaction to product containing lactobacillus
- •Active colitis (see definition below)
- •Treatment with an antibiotic with activity against VRE
- •Life expectancy less than one year or life-threatening condition
- •Known or suspected allergies to probiotics, lactobacillus, milk protein, and microcrystalline cellulose
- •Structural heart disease, history of endocarditis or valve replacement
- •Positive baseline stool culture for LGG
- •Recent or planned chemotherapy or radiation therapy
- •Solid organ transplant within the prior year
- •Stem cell transplant within the prior year
- •On active immunosuppressive medication [anti-rejection, injectable immunosuppressive drugs for autoimmune disease, or corticosteroids (greater than 1/2 mg per kg body weight of prednisone or its equivalent) not including inhaled or topical steroids]
- •Allergy or intolerance to or contraindication to two or more of the rescue antibiotic regimens (ampicillin, clindamycin, moxifloxacin)
- •Colitis will be defined as a history of Crohn's disease or ulcerative colitis with active diarrhea, active diarrhea due to Clostridium difficile infection, active diarrhea due to known or unknown cause with a stool specimen showing fecal leukocytes (if none has been done in such a patient this will be requested prior to enrollment). Diarrhea will be defined as more than three unformed bowel movements per day. The subject's primary physician will be asked to assess the subject's life expectancy, and subjects with an estimated life expectancy of less than one year as judged by the physician who knows him or her best will be excluded.
结局指标
主要结局
The primary endpoint will be the proportion of patients with VRE at one week after cessation of administration of study medication or placebo.
时间窗: Day 21post enrollment
次要结局
- That LGG can be used safely and without significant side effects in both hospitalized and ambulatory patients.(day 0-56 and 6 mnths)
- That among those treated with LGG, the colony counts of VRE will be lower when compared to controls even among those in whom colonization is not eliminated.(day 0,7,14,21,28,56)
- The rate of LGG colonization in study population receiving LGG compared to placebo.(days 21, 28, 56)
- The rate of VRE colonization in LGG recipients versus controls at 2 weeks and 6 weeks post discontinuation of administration of LGG or placebo.(2 weeks, and 6 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Probiotic Efficacy in VRE EradicationVRE ColonizationNCT03560700Hvidovre University Hospital81
Unknown
4 期
Impact of Probiotic Regimen on Vancomycin Resistant Enterococcus Intestinal CarriageVancomycin Resistant Enterococcus Intestinal CarriageNCT00437580University Hospital, Clermont-Ferrand24
已完成
4 期
The Use of Probiotics to Evaluate Colonization With Antimicrobial Resistant BacteriaInfectious Disease of Digestive TractNCT01551186Washington University School of Medicine103
已完成
3 期
Lactobacillus GG in the Prophylaxis of Ventilator Associated PneumoniaVentilator Associated PneumoniaPneumoniaNCT00613795Creighton University125
进行中（未招募）
不适用
Efficacy of Lactobacillus Rhamnosus GG on preventing acute phases in patients affected by allergic conjunctivitis - NDallergic conjunctivitisMedDRA version: 9.1Level: LLTClassification code 10010744Term: Conjunctivitis allergicEUCTR2007-000209-31-ITIVERSITA CAMPUS BIOMEDICO